title: A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients.
abstract: OBJECTIVE
  To compare the ocular hypotensive effect of tafluprost with prostaglandin analogues (PGAs) in glaucoma patients.
  
  
  METHODS
  89 primary open-angle glaucoma patients treated with bimatoprost, latanoprost, or travoprost for at least 3 months complaining for ocular discomfort were switched to tafluprost. IOP was assessed at baseline and 3 months after switching the therapy by daily curve. Primary outcome was to compare the mean daily IOP of tafluprost with PGAs.
  
  
  RESULTS
  The mean daily IOP was 16 ± 2.1 and 16.6 ± 2.0 mm Hg at baseline and after switching to tafluprost, respectively (P > 0.05). When analysis was carried out between tafluprost and each previous PGAs, the comparison between latanoprost and tafluprost and travoprost and tafluprost did not show any statistically significant difference in mean daily IOP and at each time point. The comparison between bimatoprost and tafluprost showed a statistically significant difference in mean daily IOP (P < 0.05) and at each time point (P < 0.05).
  
  
  CONCLUSIONS
  After 3 months of switching tafluprost showed an overall IOP lowering effect similar to others PGAs. When each PGA was compared with tafluprost, bimatoprost showed to provide a statistically significant additional IOP lowering effect.
authors.affiliation: Eye Clinic, San Giuseppe Hospital, University of Milan, Via San Vittore 12, Milan, Italy. stefanoranno@yahoo.it
authors.forename: Stefano
authors.initials: S
authors.lastname: Ranno
authors.forename: Matteo
authors.initials: M
authors.lastname: Sacchi
authors.forename: Cinzia
authors.initials: C
authors.lastname: Brancato
authors.forename: Daniela
authors.initials: D
authors.lastname: Gilardi
authors.forename: Andrea
authors.initials: A
authors.lastname: Lembo
authors.forename: Paolo
authors.initials: P
authors.lastname: Nucci
mesh_terms: D000368:Aged; D000577:Amides / Q000494:pharmacology; D000069580:Bimatoprost; D003008:Cloprostenol / Q000031:analogs & derivatives / Q000494:pharmacology; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007429:Intraocular Pressure; D000077338:Latanoprost; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000494:pharmacology; D011310:Preservatives, Pharmaceutical / Q000494:pharmacology; D011446:Prospective Studies; D011460:Prostaglandins F / Q000494:pharmacology*; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology; D011465:Prostaglandins, Synthetic / Q000494:pharmacology*; D013997:Time Factors; D000069557:Travoprost; D016896:Treatment Outcome
chemical_list: D000577:Amides; D009883:Ophthalmic Solutions; D011310:Preservatives, Pharmaceutical; D011460:Prostaglandins F; D011461:Prostaglandins F, Synthetic; D011465:Prostaglandins, Synthetic; C485333:tafluprost; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost; D000069557:Travoprost